| |
|
Infectious Diseases
Several viruses such as Kaposi’s sarcoma herpes virus, the Epstein-Barr virus, as well as hepatitis C and B viruses
have been recognized as oncogenic. The replication of these viruses is dependent on uninterrupted signaling through
the Ras/Raf/MEK/MAPK signal transduction pathway.
The validation of NexusPharma's Ras-Raf interaction inhibitors as effective
anti-oncogenic agents may be expected to have a significant impact in the treatment
of many chronic, widely distributed, and debilitating viruses that currently
lack effective treatments and pose significant public health burdens. First
results demonstrated the ability of NexusPharma's compounds to inhibit anchorage-independent
growth and proliferation of cells transformed with viral oncoproteines.
|
|
